Plus Therapeutics (NASDAQ: PSTV) has announced that the American Medical Association (AMA) has approved a new proprietary laboratory analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide Cerebrospinal Fluid (CSF) tumor cell enumeration (TCE) test, effective July 1, 2026.
In a statement, Marc H. Hedrick, MD, president and CEO of Plus, commented, “Securing a dedicated PLA code for CNSide is an important milestone supporting the commercial launch of our CNSide Diagnostics business. This coding milestone simplifies the reimbursement pathway for the CNSide CSF Tumor Cell Enumeration test and supports broader clinical adoption by oncologists and neurologists managing patients with leptomeningeal metastases.”
Dr. Hedrick added, “As awareness and payer coverage expand, we believe CNSide has the potential to become an important tool in the management of metastatic CNS cancers while contributing meaningfully to our revenue growth. Our diagnostics business continues to scale alongside our therapeutic pipeline, and we remain focused on building CNSide into a sustainable commercial franchise.”
